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Abstract
Female sterilisation is an extensively used method of contraception all over the world but there appears to
be a decline in the performance of this procedure in Ireland. There also appears to be an increased uptake
of safe, long-acting contraceptive alternatives. We set out to establish the extent of the decline of
laparoscopic sterilisation and to explore possible explanations. Data for female sterilisation from Ireland
was obtained from the Hospital In-Patient Enquiry Scheme (HIPE) section of the Economic and Social Research
Institute for the years 1999 to 2004. Recent sales figures for long acting reversible contraceptives,
specifically the levo-norgestrel-loaded intrauterine system (LNG-IUS) (Mirena) and the etonogestrel implant
(Implanon) were also obtained. Laparoscopic tubal ligations reduced from 2,566 (1999) to 910 (2004). In the
corresponding period the use of Mirena coils increased from 4,840 (1999) to 17,077 (2004).
Introduction
Female sterilisation, which is also called tubal ligation or tubal occlusion, is the most widely used
contraceptive method in the world today1-3. From 1950 until 1982 the number of couples using voluntary
sterilisation increased thirty fold. Over a hundred million women of childbearing age have been sterilized
and it is estimated that more than 100 million women in the developing world alone will seek sterilisation
in the next 20 years4. In 2001, in Great Britain, 10% of women aged 16-49 years had been sterilized5. A study
of the General Practice Research Database6 data suggests that in 1999 an estimated 47,268 tubal occlusions
were performed in England in the National Health Service (NHS) and charitable sectors.
Sterilisation became widely available in Ireland in the early 1980s, amid considerable controversy. Its
non-availability, for religious and ethical reasons, in certain institutions was a source of debate. While
sterilisation at time of repeat caesarean section (usually third or more) remains a popular option with
Irish patients, there has been a notable decline in the number of âintervalâ (i.e. between pregnancies)
sterilisations which are usually performed laparoscopically, as a day-case procedure, most commonly with
application of Filshie clips. Over the last decade a number of novel, safe, long-acting, progestogen-loaded,
reversible contraceptives have also become available. We set out to establish the extent of the decline of
laparoscopic sterilisation and to explore possible explanations.
Methods
Data for female sterilisation from Ireland was obtained from the Hospital In-Patient Enquiry Scheme (HIPE)
section of the Economic and Social Research Institute for the years 1999 to 2004. The first year for which
returns of this data was obligatory was 1999 and from 2005 the coding scheme was modified and now uses the
ICD-10-A (The Australian Modification of ICD-10 incorporating the Australian Classification of Health
Interventions). Recent sales figures for long acting reversible contraceptives, specifically the
levonorgestrel-loaded intrauterine system (LNG-IUS) (Mirena) and the etonogestrel implant (Implanon) were
obtained from their suppliers, Schering (Ireland) and Organon (Ireland) respectively.
The HIPE Scheme is a computer based health information system designed to collect medical and administrative
data regarding discharges and deaths from acute hospitals. Each HIPE discharge record represents one episode
of care and patients may have been admitted to more than one hospital with the same or different diagnoses.
The records therefore facilitate analyses of hospital activity rather than âincidenceâ of disease. In
the current study, all laparoscopic and open sterilisation procedures, which have individual codes depending
on the method of tubal occlusion or destruction, were divided into two simple groups, laparoscopic or open
(which include procedures carried out at time of Caesarean section).
Results
HIPE data for female sterilisation from Ireland were obtained for the years 1999 to 2004 (Table 1). These
show a marked reduction in the number of laparoscopic sterilisation procedures performed. Laparoscopic tubal
ligations fell from 2,566 to 910 during the study period, a 65% decrease. The LNG-IUS (Mirena) received its
first license in Ireland for contraception in October 1998. It was licensed as a treatment for idiopathic
menorrhagia in October 1999. During the same period (1999-2004) the annual sales of the device increased
from 4,840 to 17,077 units (a 350% rise). The etonogestrel implant, Implanon, is a long-acting reversible
contraceptive. It is a sub-dermal implant and is effective for three years. Implanon was launched in Ireland
in 2001 and from 2002 to the end of 2005 over 30,000 units were distributed in Ireland (Table 1).
Discussion
We are satisfied that the HIPE data provide a reasonable estimate of female sterilisation activity since the
returns have been obligatory since 1999 and the totals are thought to represent 95% of national coverage by
the Department of Health and Children. We have shown a dramatic decline in laparoscopic sterilisation in
Ireland in recent years. This decline has coincided with the introduction of progestogen-loaded
contraceptive devices, particularly the LNG-IUS, which has seen a huge increase in sales over the same
period.
The swiftness of the change in medical practice probably suggests that this has been physician led, rather
than patientdemand led, from the outset. It may reflect that doctors, particularly gynaecologists, were not
very enthusiastic about laparoscopic sterilisation and were eager to adopt potentially safer and reversible
alternatives. No remarkable decline in nonlaparoscopic sterilisation (which are almost all performed at time
of Caesarean section) was observed. This suggests that there is no aversion to sterilisation per se among
obstetricians or patients but rather to the method involved.
Issues likely to have been responsible for the change in medical practice include reversibility, safety and
the availability of reliable alternatives. Reversibility is an important feature of contraception as regret
and requests for reversal or in-vitro fertilization are not uncommon after sterilisation. In a US
Collaborative Review of Female Sterilisation7,8, among 11,232 women, the 14-year cumulative probability of
expressing regret was 20.3% for women aged 30 or younger at the time of sterilisation and 5.9% for women
over age 30 at sterilisation. The 14-year cumulative probability of requesting reversal information was
14.3% and the overall cumulative probability of obtaining reversal was 1.1%.
Female sterilisation is a surgical procedure and is therefore unusual in that the indication for surgery is
generally patient request for social reasons and not a treatment prescribed by a doctor for medical reasons.
Also, its intended permanency means the onus is on the doctor to ensure that the patient has all the
information required to make an informed decision. This is important, as female sterilisation is a frequent
cause of medical litigation9-11. Major morbidity caused by laparoscopic sterilisation is a rare event but
serious complications can occur. These include major complications such as injuries to bowel, bladder or
blood vessels that require laparotomy or lead to death. The risk of laparotomy as a result of a severe
complication in one large prospective study12 was 1.9/1,000 procedures with two other practice surveys13,14
recording laparotomy rates of 1.4â3.1/1,000 cases. The risk of death with a laparoscopy is one in 12,000 12.
Some women are at increased risk from conditions such as previous abdominal surgery or obesity. Previous
abdominal or pelvic surgery, previous pelvic inflammatory disease and obesity significantly increase the
relative risk of complications and need for laparotomy15,16. Many women in Ireland now have had at least one
Caesarean section. Between 40-50% of Irish women are either overweight (BMI = 25.0-29.9) or obese (BMI  30)
and the prevalence of pelvic inflammatory disease is also increasing17.
Some of the newer long-acting contraceptive methods are as effective as tubal occlusion and yet preserve
reversibility and have the huge advantage of being office procedures, requiring relatively little training,
and with very small risk of procedure-related injury. The cumulative pregnancy rate for the LNG-IUS is
1.1/100 after five years of typical use18.
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In our own units, laparoscopic sterilisation has almost disappeared completely. Some consultants stopped
offering the procedure once the LNG-IUS became available as an alternative. There was little resistance from
patients or from referring physicians and it is apparent that the change in policy has been broadly
accepted. Thus, it would seem that a procedure that was introduced in Ireland to considerable furore is
becoming rapidly obsolete. Many will have no regrets about its passing.
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